---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-000157"
form_type: "8-K"
ticker: "HRMY"
cik: "0001802665"
company_name: "Harmony Biosciences Holdings, Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:43:17.770427+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Harmony Biosciences: Q4 WAKIX revenue ~$201M, FY2024 ~$714M; guides 2025 $820-860M

## Summary
- Preliminary Q4 2024 net product revenue ~$201M (vs $168.4M Q4 2023); FY2024 ~$714M (vs $582M, +23% YoY).
- 2025 net revenue guidance of $820-860M, implying continued growth toward $1B+ opportunity.
- Pipeline catalysts: FDA decision on pitolisant sNDA for idiopathic hypersomnia expected Q1 2025; potential approval in 2025.
- Phase 3 topline data for ZYN002 in Fragile X syndrome expected Q3 2025; Pitolisant-HD Phase 3 in narcolepsy to start Q4 2025.
- Average patients on WAKIX increased to ~7,100 in Q4 2024, up ~300 sequentially.

## SEC filing metadata
- accession: 0001558370-25-000157
- form_type: 8-K
- ticker: HRMY
- cik: 0001802665
- company_name: Harmony Biosciences Holdings, Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802665/000155837025000157/0001558370-25-000157-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802665/000155837025000157/hrmy-20250113x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-000157
- JSON: https://secwatch.observer/filing/0001558370-25-000157.json
- Plain text: https://secwatch.observer/filing/0001558370-25-000157.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.